Data from FDA (Food and Drug Administration, USA) - Curated by EPG Health - Last updated 17 February 2017
If hepatic and
Discontinuation of Thermazene® should be weighed against the therapeutic
In considering the use of topical proteolytic enzymes in conjunction with Thermazene® the possibility should be noted that
In the treatment of
Therefore, in these patients it would be advisable to monitor serum sulfa concentrations.
Absorption of the propylene glycol vehicle has been reported to affect serum osmolality, which may affect the interpretation of laboratory tests.
Rebound to normal leukocyte levels follows onset within two to three days.
Recovery is not influenced by continuation of
Other infrequently occurring events include skin necrosis, erythema multiforme, skin
Reduction in bacterial
However, reduction in bacterial colonization has caused
DOSAGE AND ADMINISTRATION Prompt institution of
The cream should be applied once to twice daily to a thickness of approximately one sixteenth of an inch.
Whenever necessary, the cream should be reapplied to any areas from which it has been removed by patient activity.
However, if individual patient requirements make dressings necessary, they may be used.
Reapply immediately after hydrotherapy.
Treatment with Thermazene® should be continued until
The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of
It is not known whether Thermazene® is excreted in human milk.
However, sulfonamides are known to be excreted in human milk and all sulfonamides derivatives are known to increase the possibility of kernicterus.
Because of the possibility for serious
|Agency product number||W46JY43EJR|
|Date Last Revised||15-01-2015|
|Type||HUMAN PRESCRIPTION DRUG|
|Marketing authorisation holder||The Pharma Network LLC|